IONIS PHARMACEUTICALS, INC. (IONS) DISCUSSES FDA APPROVAL OF TRYNGOLZA FOR SEVERE HYPERTRIGLYCERIDEMIA AND ACUTE PANCREATITIS RISK REDUCTION TRANSCRIPT — via SEEKINGALPHA
FDA approval catalyst for severe hypertriglyceridemia and pancreatitis risk reduction.
What changed
FDA approval catalyst for severe hypertriglyceridemia and pancreatitis risk reduction.
Why it matters
FDA approval catalyst for severe hypertriglyceridemia and pancreatitis risk reduction. — impact context not separately stored; see What changed.
← Dashboard
Jun 25, 2026 06:43 PM ET